Name: Equity Multiplier

Definition: The equity multiplier shows how much total assets the company controls for every dollar invested by shareholders. It reflects how much debt is being used to stretch owners’ equity. A higher multiplier means greater use of debt to amplify returns — but also amplifies risk if things go wrong. Lower multipliers suggest a safer, more self-funded business.

Interpretation:
• In '2022', ROIV's equity multiplier was 1.56, representing the level of financial leverage utilized. Industry average for Biotechnology: Pharmaceutical Preparations in '2022' stood at 1.36.
• In '2023', ROIV's equity multiplier was 2.06, representing the level of financial leverage utilized. The increase compared to '2022' may signal growing financial pressure. Industry average for Biotechnology: Pharmaceutical Preparations in '2023' stood at 1.19. Industry average declined by 0.17 from previous year.
• In '2024', ROIV's equity multiplier was 1.21, representing the level of financial leverage utilized. The decrease since '2023' reflects improving financial health. Industry average for Biotechnology: Pharmaceutical Preparations in '2024' stood at 1.53. Industry average increased by 0.34 compared to previous year.
• In '2025', ROIV's equity multiplier was 1.16, representing the level of financial leverage utilized. The decrease since '2024' reflects improving financial health. Industry average for Biotechnology: Pharmaceutical Preparations in '2025' stood at 1.51. Industry average declined by 0.03 from previous year.
Overall, ROIV's equity multiplier has been volatile but showed a downward trend over the past 4 years.

Formula: Equity Multiplier = Total Assets / Shareholders' Equity

Good Range: Usually ranges from 1.5 to 3 depending on industry.